Litcius/Paper detail

Real‐world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

Luca Lanino, Francesco Restuccia, Alessandra Perego, Marta Ubezio, Bruno Fattizzo, Marta Riva, Angela Consagra, Pellegrino Musto, Daniela Cilloni, Esther Natalie Olíva, Raffaele Palmieri, Antonella Poloni, Catello Califano, Isabella Capodanno, Federico Itri, Chiara Elena, Claudio Fozza, Fabrizio Pane, Anna Maria Pelizzari, Massimo Breccia, Francesco Di Bassiano, Elena Crisà, Dario Ferrero, Valentina Giai, Daniela Barraco, A Vaccarino, Davide Griguolo, Paola Minetto, Martina Quintini, Stefania Paolini, Grazia Sanpaolo, Mariarosaria Sessa, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Livia Leuzzi, Angelo Genua, Attilio Guarini, Alfredo Molteni, Barbara Nicolino, Ubaldo Occhini, Giulia Rivoli, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Felicetto Ferrara, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Marco Frigeni, Rosaria Sancetta, Carmine Selleri, Ilaria Tanasi, Patrizia Tosi, Mauro Turrini, Laura Giordano, Carlo Finelli, Paolo Pasini, Ilaria Naldi, Valeria Santini, Matteo Giovanni Della Porta

2023American Journal of Hematology17 citationsDOIOpen Access PDF

Abstract

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts

Topics & Concepts

MedicineMyelodysplastic syndromesAnemiaInternal medicineInternational Prognostic Scoring SystemPopulationBone marrowEnvironmental healthAcute Myeloid Leukemia ResearchMyeloproliferative Neoplasms: Diagnosis and TreatmentHemoglobinopathies and Related Disorders